The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

See Cruse A et al. A case of sacituzumab-induced pneumonitis. Chest 2023; 164 (45) 3316A

Publications

Mathew N, Joel A, Andrews AG, John AO, Singh A

CDK 4/6 inhibitor induced lung injury: a case report and review of literature.

Ecancermedicalscience. 2021;15:1245

Nawa H, Niimura T, Yagi K, Goda M, Zamami Y, Ishizawa K

Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments.

Cancer reports (Hoboken, N.J.). 2022;5(1):e1402

Felip E, Llobera L, Perez-Mañá C, Quintela D, Guasch I, Margelí M, Teruel I, Cirauqui B, Centeno C, Romeo M, Ballana E, Quiroga V

New Drugs, Old Toxicities: Pneumonitis Related to Palbociclib - A Case Report.

Breast care (Basel, Switzerland). 2020;15(5):548-552

Jazieh KA, Budd GT, Dalpiaz N, Abraham J

Can CDK4/6 inhibitors cause fatal lung injury?

Expert review of anticancer therapy. 2019;19(11):917-919